Navigation Links
Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test
Date:6/7/2008

A Powerful New Tool for Early Identification of High Risk Patients Early

Intervention Can Help Prevent Disease Progression

SAN FRANCISCO, June 7 /PRNewswire/ -- Tethys Bioscience, Inc. announced today at the 68th Scientific Sessions of the American Diabetes Association (ADA) that it has expanded the availability of its novel PreDx(TM) Diabetes Risk Test, a first-of-its-kind predictive tool that delivers an accurate assessment of an individual's risk of developing Type 2 diabetes within the next five years. The test is performed exclusively by the Tethys Bioscience Clinical Laboratory on routinely collected blood samples.

The new blood test is designed to help physicians identify patients at highest risk of developing Type 2 diabetes so that they can promote lifestyle changes or initiate treatment plans to prevent or slow progression to Type 2 diabetes. Numerous studies have demonstrated that such interventions can reduce the incidence of new onset diabetes by 30-60%.

"There are a number of proven methods that clinicians can use to delay or prevent Type 2 diabetes in high-risk people," said Dr. Thomas Buchanan, Professor of Medicine at the University of Southern California Keck School of Medicine. "The problem has been the lack of an easy-to-use clinical test to identify the high-risk people. The PreDx Diabetes Risk Test solves that problem. For the first time, clinicians can order a single blood test to assess their patients' diabetes risk and identify those who are in greatest need of diabetes prevention. This is a real paradigm shift."

Using data generated from thousands of patients who were monitored for up to 17 years, Tethys identified specific proteins and other biomarkers that are most predictive of a person's progression to Type 2 diabetes. Through comprehensive analysis of proteins and integration of multiple risk-defining biomarkers, the company developed a sophisticated test capable of stratifying at-risk in
'/>"/>

SOURCE Tethys Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
2. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestones in Plant Agriculture Collaboration
3. Georgia Showcases its Bioscience Leadership at 2008 Bio International Convention
4. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. Sangamo BioSciences to Present at the Canaccord Adams Diabetes and Obesity Conference
7. Dow AgroSciences, Martek Biosciences Form Alliance to Bring Omega-3 Fatty Acids to Food Industry
8. Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
9. Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
10. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
11. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email: